Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities

Basit Öğe Kaydı
dc.contributor.authorAskarizadeh, Fatemeh
dc.contributor.authorKarav, Sercan
dc.contributor.authorJamialahmadi, Tannaz
dc.contributor.authorSahebkar, Amirhossein
dc.date.accessioned2025-01-27T20:22:24Z
dc.date.available2025-01-27T20:22:24Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractStatins are widely utilized to reduce cholesterol levels, particularly in cardiovascular diseases. They interface with cholesterol synthesis by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase enzyme. Besides their primary effect, statins demonstrate anti-inflammatory and immune-modulating properties in various diseases, highlighting the pleiotropic effect of these drugs. The CD40:CD40L signaling pathway is considered a prominent inflammatory pathway in multiple diseases, including autoimmune, inflammatory, and cardiovascular diseases. The findings from clinical trials and in vitro and in vivo studies suggest the potential anti-inflammatory effect of statins in modulating the CD40 signaling pathway and downstream inflammatory mediator. Accordingly, as its classic ligand, statins can suppress immune responses in autoimmune diseases by inhibiting CD40 expression and blocking its interaction with CD40L. Additionally, statins affect intracellular signaling and inhibit inflammatory mediator secretion in chronic inflammatory diseases like asthma and autoimmune disorders such as myasthenia gravis, multiple sclerosis, systemic lupus erymanthus, and cardiovascular diseases like atherosclerosis. However, it is essential to note that the anti-inflammatory effect of statins may vary depending on the specific type of statin used. In this study, we aim to explore the potential anti-inflammatory effects of statins in treating inflammatory diseases by examining their role in regulating immune responses, particularly their impact on the CD40:CD40L signaling pathway, through a comprehensive review of existing literature.
dc.identifier.doi10.1007/s43440-024-00678-2
dc.identifier.issn1734-1140
dc.identifier.issn2299-5684
dc.identifier.pmid39680334
dc.identifier.scopus2-s2.0-85212254162
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s43440-024-00678-2
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21863
dc.identifier.wosWOS:001378371900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Heidelberg
dc.relation.ispartofPharmacological Reports
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectStatins
dc.subjectCD40
dc.subjectCD40L
dc.subjectImmunomodulating drugs
dc.subjectTherapeutic effect
dc.subjectAnti-inflammatory agent
dc.subjectCardiovascular disease
dc.titleImpact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu